Evaluating Serum Surfactant Protein-D, KL-6, and Deep Learning Approaches on Chest X-rays for Lung Fibrosis Detection: A Prospective Observational Investigation - Takeaways - MDSpire

Evaluating Serum Surfactant Protein-D, KL-6, and Deep Learning Approaches on Chest X-rays for Lung Fibrosis Detection: A Prospective Observational Investigation

  • By

  • Hirotaka Nishikiori

  • Naoya Yama

  • Kenichi Hirota

  • Yuki Mori

  • Ippei Neriai

  • Haruka Takenaka

  • Atsushi Saito

  • Mamoru Takahashi

  • Koji Kuronuma

  • Shinichiro Ueda

  • Masamitsu Hatakenaka

  • Hirofumi Chiba

  • December 17, 2025

  • 0 min

Share

  • 1

    Lung fibrosis detection is crucial for improving outcomes in patients with idiopathic pulmonary fibrosis and other fibrosing interstitial lung diseases.

  • 2

    Serum biomarkers surfactant protein-D and KL-6 are used in Japan to monitor disease activity in interstitial lung disease patients.

  • 3

    A deep learning algorithm, BMAX, was developed to detect fibrosing interstitial lung disease on chest radiographs and is commercially available.

  • 4

    The study evaluated the effectiveness of BMAX and serum biomarkers in detecting lung fibrosis during routine health checkups.

  • 5

    Chest CT scans were used for secondary screening to confirm lung fibrosis in participants identified through initial evaluations.

Original Source(s)

Evaluating Serum Surfactant Protein-D, KL-6, and Deep Learning Approaches on Chest X-rays for Lung Fibrosis Detection: A Prospective Observational Investigation

  • by Hirotaka Nishikiori, Naoya Yama, Kenichi Hirota, Yuki Mori, Ippei Neriai, Haruka Takenaka, Atsushi Saito, Mamoru Takahashi, Koji Kuronuma, Shinichiro Ueda, Masamitsu Hatakenaka, Hirofumi Chiba

  • December 17, 2025

Related Content

AI-Driven Assessment of Fibrotic and Vascular Changes Correlates with Patient Outcomes in Idiopathic Pulmonary Fibrosis

Cataract Risk Elevated in Pneumoconiosis

Researchers assess whether occupational lung disease is linked to long-term eye outcomes.

IPF Cough: Opioid-Based Approach Tested

Researchers examine oral nalbuphine for chronic cough in IPF, using objective digital monitoring and patient-reported measures.